Actinogen Medical
Professor Walker’s prolific research over 20 years has concerned the role of glucocorticoids in metabolic syndrome and cardiovascular disease. He published the original description of 11β-HSD1’s role in amplifying glucocorticoid action, identifying this enzyme as a prime therapeutic target. He has extensive experience collaborating with and advising pharmaceutical research and development.
In 2017, Brian was appointed as Pro Vice Chancellor for Research Strategy & Resources at Newcastle University, UK. He continues his research on glucocorticoids with colleagues at University of Edinburgh.
This person is not in the org chart
This person is not in any offices
Actinogen Medical
1 followers
FOCUSED ON DEVELOPING AN INNOVATIVE TREATMENT FOR COGNITIVE IMPAIRMENT due to raised cortisol ASSOCIATED WITH NEUROLOGICAL DISEASES Ethics Committee approval for XanaMIA StudyActinogen has received approval from the Bellberry Human Research Ethics Comm...